Intellia Therapeutics faces a downgrade amid Nex-z safety concerns, impacting investor outlook. Read more here.
The researchers discovered that this separation proves remarkably clean. In a preprint paper released in late October, they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback